<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000419"><gtr:id>486715FB-D9D6-4F9C-961B-8AF13FDD5DCE</gtr:id><gtr:title>Scottish Clinical Pharmacology &amp;amp; Pathology Programme (SCP3)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000419</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Scotland offers a world-class environment in which to train future clinical academic leaders.
We propose an exciting clinical research fellowship programme (SCP3) that will integrate
clinical pharmacology and pathology training across the Scottish Biomedical Universities. We
will thereby break the mould of two traditional ?ologies? by integrating training in the combined
competencies necessary to dissect complex pathogenesis and promote mechanism-based
medicine discovery. SCP3 is built on the notion that mechanistic (pathology)-based approaches
comprise an essential prerequisite to successful elucidation of pathogenesis, and therefore
drug discovery, development and evaluation in a ?translational medical? environment. A
corollary is that research in the UK can be optimised by integrated training for future
translational medicine leaders in these disciplines from an early stage. SCP3 will operate within
an outstanding research environment ideally suited to achieve this goal. Evidence for such
research and environmental excellence resides in excellent recent RAE performance and in
consistent, competitive levels of grant income and publication productivity. The rich project
resource available to fellows will encompass organ- or tissue-based themes, but will include
the opportunity to combine clinical pharmacology and pathology supervisorial teams to truly
integrate state-of-the-art molecular/cellular pathology techniques to foster drug development
and pathogenesis discovery. Moreover we bring strong, established partnership with Pfizer
that will benefit SCP3 both through provision of industrial placements and through access to
the state of the art Translational Medicine Research Institute.
The programme will focus in the disciplines of cardiovascular, metabolic and inflammation
medicine and cancer representing areas of global unmet clinical need and reflecting areas of
conspicuous research excellence in Scotland. Fellows selected on the basis of individual
excellence will receive comprehensive training in generic skills that will add value to high
quality core research training, providing an overall mixture of didactic and flexible
laboratory/clinical research based training. Excellent mentorship and supervision built into a
flexible programme will ensure a tailored approach to the needs of individual fellows. A robust
oversight structure is proposed to ensure prompt recruitment and ongoing management of the
programme. We will offer the unique added value of ?run through training? to appointed fellows
such that upon satisfactory progress, each recruit will be offered a lecturer position within
discipline to facilitate training to senior appointment level. SCP3 will therefore generate a cadre
of high quality clinical academics in clinical pharmacology and pathology with the necessary
skills to drive forward clinical research excellence in the next decades.</gtr:technicalSummary><gtr:fund><gtr:end>2017-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1933711</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B91A9E8C-32CB-4D3F-B24F-D6076595ADF6</gtr:id><gtr:title>The development of prognostic and predictive biomarkers in renal cell cancer are not one and the same thing.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f346386c513bb4933b76fee2a584d9"><gtr:id>34f346386c513bb4933b76fee2a584d9</gtr:id><gtr:otherNames>Laird A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>546a19f5efb2b3.13408075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>186A5A8F-EFF8-467B-868D-C6B5C5FC627E</gtr:id><gtr:title>The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f2336890aa43969542a2a3c8b1d4702"><gtr:id>7f2336890aa43969542a2a3c8b1d4702</gtr:id><gtr:otherNames>O'Mahony FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>5469e4247291a3.76444510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25AEFBBC-0AA1-4127-992E-A03D948980B4</gtr:id><gtr:title>5-hydroxymethylcytosine profiling as an indicator of cellular state.</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f346386c513bb4933b76fee2a584d9"><gtr:id>34f346386c513bb4933b76fee2a584d9</gtr:id><gtr:otherNames>Laird A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>5469e42426d122.30742187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B588AD77-A5A5-4DC5-9A8A-0374D3FC0639</gtr:id><gtr:title>N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1879cf77e5158dd3c9b1fb0724cc2274"><gtr:id>1879cf77e5158dd3c9b1fb0724cc2274</gtr:id><gtr:otherNames>Yu X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>pm_55f9550955053689d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABDC2868-9427-4B0F-A695-A5DE87660BBB</gtr:id><gtr:title>Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c37f799329bbe36bda8a1ed60d551c"><gtr:id>72c37f799329bbe36bda8a1ed60d551c</gtr:id><gtr:otherNames>Stewart GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5460b48e3eda47.64029916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACEA3382-8690-4A8A-A9F8-39F6C1A49CE5</gtr:id><gtr:title>Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c5c2253c4ba1d1ab5829aa152019a46"><gtr:id>7c5c2253c4ba1d1ab5829aa152019a46</gtr:id><gtr:otherNames>Li A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>546a09e19621f7.95197473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A801384-D080-4416-8FAA-D3D2A52F5EEA</gtr:id><gtr:title>Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f346386c513bb4933b76fee2a584d9"><gtr:id>34f346386c513bb4933b76fee2a584d9</gtr:id><gtr:otherNames>Laird A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5469e4244d60f4.58942941</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000419</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>